Paracetamol + Codeina Pharmakern (Acetaminophen,Codeine)

Quick links

Choose a section

Quick links to important sections

Advertisements

Paracetamol + Codeina Pharmakern (Acetaminophen,Codeine)

Advertisements
Advertisements

Method of action: Analgesic, Antitussive Opioid, Opioid

Advertisements

Overview of Paracetamol + Codeina Pharmakern (Acetaminophen,Codeine)

Understanding Paracetamol + Codeina Pharmakern

Paracetamol + Codeina Pharmakern is a fixed-dose combination medication consisting of two active ingredients: paracetamol (also known as acetaminophen) and codeine phosphate hemihydrate. This combination is classified under the pharmacotherapeutic group of analgesics and antipyretics.

Mechanism of Action

The efficacy of this medication is based on the complementary actions of its two components:

  • Paracetamol: This substance is known for its analgesic (pain-relieving) and antipyretic (fever-reducing) properties. While its exact mechanism is not fully elucidated, it is believed to act primarily by inhibiting the synthesis of prostaglandins in the central nervous system.
  • Codeine: This is an opioid analgesic. It works by acting on specific receptors in the brain and spinal cord to relieve pain. Codeine is considered a weak central analgesic that exerts its effect through its conversion into morphine within the body.

Therapeutic Purpose

This combination product is utilized for the treatment of acute moderate pain. By combining a non-opioid analgesic (paracetamol) with an opioid analgesic (codeine), the medication provides a multi-modal approach to pain management. This synergy often allows for effective pain relief in instances where single-ingredient analgesics may not be sufficient.

Regulatory References

  1. Codeine-containing medicines
Advertisements

What side effects are possible with Paracetamol + Codeina Pharmakern (Acetaminophen,Codeine)?

Possible Side Effects and Safety Information

The safety profile of Paracetamol + Codeina is documented according to established regulatory classifications, distinguishing between common reactions and serious, rare adverse events. This information is based on authoritative government regulatory sources.

Adverse Reactions by Frequency and System

Classification Examples of Documented Reactions
Common Drowsiness, lightheadedness, dizziness, nausea, vomiting, constipation, and sweating. These are primarily related to the codeine component.
Rare/Not Known Severe hepatotoxicity (liver damage/failure), severe skin reactions (e.g., Stevens-Johnson Syndrome), and hypersensitivity reactions.

Serious Adverse Reactions and Safety Constraints

Serious Adverse Reactions officially documented include life-threatening respiratory depression, especially during treatment initiation or dose increase. The paracetamol component carries a significant risk of severe hepatotoxicity (acute liver failure), which is primarily associated with exceeding the strict maximum daily dose (e.g., 4,000 mg or 3,250 mg). The drug also poses a risk of addiction, abuse, and misuse due to the opioid (codeine) component.

Population-Specific Restrictions are in place: The medicine is contraindicated in children under 12 years of age, in ultra-rapid metabolizers of codeine, and in breastfeeding mothers, due to the increased risk of serious adverse events.

Safety Restrictions require that the drug be used for the shortest possible duration. Concurrent use with alcohol or other central nervous system depressants is cautioned against due to the heightened risk of severe sedation and respiratory depression.

Advertisements

Overdose and Emergency Response

The official regulatory profile for an overdose of this combination is structured around the two primary, life-threatening toxicities of its active components, necessitating an immediate emergency response.

Overdose Scope Official Regulatory Statements
Documented Manifestations Symptoms of the paracetamol component begin with nausea, vomiting, pallor, and abdominal pain, advancing to severe acute liver failure (hepatotoxicity). The codeine component presents with opioid toxicity signs such as shallow or stopped breathing, stupor, miosis (pinpoint pupils), and potentially coma.
Severe Outcomes The risks include fatal respiratory depression and the development of Acute Liver Failure, both of which are classified as life-threatening.
Immediate Action Required Seek immediate medical attention right away, even if the individual appears well or symptoms are transient, due to the high risk of delayed, severe, and irreversible liver damage.

Emergency medical management, as documented in regulatory guidelines, requires the use of two specific antidotes: Naloxone is necessary to reverse the severe CNS and respiratory depressive effects of the codeine component, and N-acetylcysteine (NAC) is required to protect against liver damage from the paracetamol component. Both are time-critical. A population-specific high risk exists for Ultra-rapid Metabolizers, who may experience life-threatening respiratory depression due to rapid codeine conversion.

Advertisements

Therapeutic Uses of Paracetamol + Codeina Pharmakern (Acetaminophen,Codeine)

What Paracetamol + Codeina Pharmakern (Acetaminophen,Codeine) Treats: Main Uses and Benefits

This combination analgesic is used for the relief of symptoms related to physical discomfort experienced as moderate to severe pain. It is generally applied in contexts where short-term symptomatic assistance is needed and is relevant when previous symptomatic approaches may have provided insufficient relief. It is intended to address symptom clusters that may become intense or disruptive.

Commonly used across conditions presenting with acute episodes, the medication helps manage post-procedural discomfort after minor surgery or dental procedures, acute traumatic pain from sprains or strains, and musculoskeletal discomfort associated with heightened physiological strain. It is relevant when supportive symptom management is appropriate, applied during phases when symptoms become more noticeable, and may support patients during difficult episodes by easing distress and contributing to improved comfort during symptomatic periods.


Quick Fact: Relevance for Significant Pain This dual-component analgesic is used when symptom intensity is moderate to severe, and may contribute to easing the overall symptom burden during acute episodes such as post-operative recovery or traumatic injury.

Regulatory References

  1. NIH MedlinePlus Drug Information
Advertisements

Eligibility and Restrictions for Use

Eligibility and Contraindications

This medication is approved for use in adults and adolescents 12 years of age and older. Use is strictly contraindicated (prohibited) for several specific populations, primarily due to the codeine component and its metabolism.

Contraindicated Populations:

  • Children under 12 years of age.
  • All pediatric patients (0-18 years) following tonsillectomy or adenoidectomy for obstructive sleep apnoea syndrome.
  • Women who are breastfeeding.
  • Patients known to be CYP2D6 ultra-rapid metabolisers of codeine.
  • Individuals with severe hepatic insufficiency (severe liver disease) or acute respiratory depression.

Restricted or Not Recommended Use:

  • Use is not recommended during the third trimester of pregnancy.
  • Adolescents (12-18 years) with compromised respiratory function should generally not use this medicine.
  • Patients with moderate to severe renal or hepatic impairment require caution and often a reduced dose.

This eligibility profile ensures that the drug is only used when the patient's physiological state and metabolic capacity align with established safety and regulatory guidelines.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile for this combination medicine is primarily defined by the codeine component's metabolism and its central nervous system (CNS) effects, as documented in regulatory information. Co-administration with certain substances is categorized as high-risk or strictly prohibited.


Documented Interaction Categories

Interaction Type Interacting Substances/Class Formal Regulatory Outcome
Contraindicated Combinations Monoamine Oxidase Inhibitors (MAOIs) Prohibited due to documented risk of Serotonin Syndrome.
Use during Breastfeeding Prohibited due to the risk of ultra-rapid metabolism to morphine and infant toxicity.
Pharmacodynamic Other CNS Depressants (e.g., Anesthetics, Benzodiazepines, Alcohol) Additive CNS depression, leading to risk of profound sedation and respiratory depression.
Pharmacokinetic CYP2D6 Inhibitors (e.g., Paroxetine, Fluoxetine) Officially documented to decrease the active metabolite, morphine, which may result in reduced analgesic efficacy.
Pharmacokinetic CYP3A4 Modulators (Inhibitors/Inducers) Alters the plasma concentration of codeine, affecting the risk of adverse reactions or reduced efficacy.
Other Anticoagulants (e.g., Warfarin) Interaction with the paracetamol component may necessitate monitoring and dosage modification of the anticoagulant.

Population-Specific Constraints

The product is contraindicated for individuals identified as CYP2D6 ultra-rapid metabolizers due to the high risk of opioid toxicity. Additionally, official documents note that patients with hepatic or renal impairment may experience an increased effect from the medicine due to slower clearance from the body.

Advertisements

Mechanism of Action

Central Nervous System Prostaglandin Modulation

This domain covers the action of acetaminophen (Paracetamol), which primarily works by inhibiting specific cyclooxygenase (COX) enzymes within the brain and spinal cord. This targeted action reduces the synthesis of pain- and fever-mediating prostaglandins, which results in the stabilization of the body's thermoregulatory set-point and an elevated pain threshold.


Opioid Receptor Agonism for Pain Inhibition

This describes the mechanism of codeine, a prodrug that is converted to morphine, the active substance. Morphine acts as an agonist on mu (mu) opioid receptors in the central nervous system, particularly engaging the descending pain-inhibitory pathways. This action promotes an increase in descending inhibitory tone, resulting in a reduction of nociceptive signal transmission to higher brain centers, which contributes to the combination's influence on nociception.

Advertisements

Dosage and Administration Information

General Principles of Administration

Paracetamol + Codeine is a fixed-dose combination analgesic intended exclusively for oral administration, commonly supplied as tablets, capsules, or oral solutions. General guidance emphasizes using the lowest effective dosage for the shortest possible duration in the management of acute pain. This medication may generally be taken with or without food.


Official Dosing and Frequency Patterns

The frequency and strength of use are governed by established limits to mitigate risk and ensure proper use. Doses are typically separated by a minimum of four hours and should not exceed four doses in a 24-hour period when using the two-tablet regimen. The total daily intake of the paracetamol component from all sources must not exceed 4,000 milligrams (4 grams) to prevent toxicity. For common strengths, such as 500 mg Paracetamol/30 mg Codeine tablets, the maximum intake is eight tablets over a 24-hour period.

Dosing Component Maximum Daily Limit (Adults) Minimum Interval
Paracetamol (Total) 4,000 mg N/A
Combination Dose 8 tablets (500 mg/30 mg strength) 4 hours

Duration and Population Constraints

The usage protocol is strictly limited to short-term pain management. Standard protocols advise against taking the medicine for more than three consecutive days without medical review. Furthermore, the product is contraindicated in children under the age of 12 years. Dose adjustments, which may include a reduced initial dose or extended dosing intervals, are often required and must be considered for older adults and patients with hepatic or renal impairment.

Advertisements

Recent Clinical Evidence

Research evidence / Overview of studies for Paracetamol + Codeina Pharmakern (Acetaminophen, Codeine)

Evidence for Use in Acute Postoperative Pain

Short-term Randomized Controlled Trials (RCTs) and comprehensive systematic reviews were conducted during periods of increased symptom activity following minor surgical procedures. Research examined outcomes related to physical discomfort, such as the change in pain scores and the time elapsed before participants required additional (rescue) medication. These studies typically involved adults experiencing moderate to severe acute pain.

Studies monitored how symptoms evolved in the observed populations, with reports detailing the measurements of pain reduction achieved within a defined period, generally 4 to 6 hours after a single dose. The research provides context for interpreting short-term symptomatic observations following procedures.

Evidence for Use in Acute Pain of Moderate to Severe Intensity

Systematic reviews and comparative trials were applied in studies examining patient-reported experiences related to significant, acute pain. This research explored outcomes describing episodic or acute changes and measured against both placebo and paracetamol administered alone. Study populations included general adults and, in some cases, adolescents aged 12 and older.

Findings describe patterns observed in the studies regarding the proportion of participants who reported adequate symptom management during the study period. Research explores the differences in measurements of pain intensity between the combination product and its single components.

Evidence for Musculoskeletal Pain (Acute Episodes)

Specific high-quality comparative trials for the use of this combination in acute musculoskeletal pain (like strains or sprains) are limited. Research examined outcomes reflecting daily functioning or activity level, alongside measures of pain intensity reduction. The evidence base for this specific context is described in some reviews as having fewer dedicated primary studies.

Areas of Research Uncertainty and Study Gaps

The vast majority of research focusing on this combination was observed in studies exploring short-term symptom changes (e.g., a few hours). This focus means there is limited information regarding outcomes for extended use. A major limitation is the influence of genetic factors on individual response, which was observed in some studies to introduce variability. This suggests research provides context but not individual predictions regarding symptom patterns. Comparative evidence is lacking in certain areas against contemporary non-opioid medications.

Key Studies & References

  1. ACETAMINOPHEN AND CODEINE PHOSPHATE tablet - DailyMed (NIH/FDA Drug Label)
  2. Combination analgesics in adults (Australian Prescriber/Therapeutic Guidelines - Musculoskeletal/General Acute Pain Evidence)
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Paracetamol + Codeina Pharmakern (Acetaminophen,Codeine) (FAQ)

Q: Is this combination medicine stronger than just paracetamol alone?

A: Regulatory reviews that compare the combination product against paracetamol administered alone describe a statistically significant, comparatively small increase in the analgesic (pain-relieving) effect. Official information indicates that the combined effect of paracetamol and codeine is intended to manage pain that is not sufficiently relieved by non-opioid medicines alone.

Q: Is it common to feel drowsy or sleepy after taking this drug?

A: Yes, official regulatory documents list drowsiness and sleepiness as a common documented adverse reaction. These effects are primarily related to the codeine component, which acts on the central nervous system. Awareness of this potential effect is relevant when planning daily activities.

Q: Can taking this medicine cause constipation?

A: Yes, regulatory documents list constipation as a common documented adverse reaction. This side effect is linked to the codeine component, which can slow movement in the digestive system. This is a recognized effect of opioid-based medicines.

Q: Is it safe to take this drug if I already take a prescription antidepressant?

A: Regulatory information notes that some prescription antidepressants are classified as CYP2D6 inhibitors. This can interfere with how your body converts codeine into its active pain-relieving form. This interaction may result in reduced efficacy, meaning the medicine may not work as well for pain relief. Information regarding the compatibility of this medicine with specific prescription antidepressants is best discussed with a healthcare professional.

Q: Can I use this medicine if I'm also taking over-the-counter cold medication?

A: The primary safety warning here relates to the paracetamol component. Regulatory guidance strictly limits the maximum daily intake of paracetamol from all sources to 4,000 mg to prevent liver toxicity. If other concurrent medicines, such as cold medication, contain paracetamol (acetaminophen), there is a documented risk of exceeding the safe daily limit when also using the combination drug.

Q: Does this combination interact with alcohol, even a small amount?

A: Official warnings state that this combination medicine should not be used with alcohol. Alcohol can enhance the drug's effects on the central nervous system (CNS), which significantly increases the risk of additive CNS depression, severe sedation, and life-threatening respiratory problems.

Q: Is Paracetamol + Codeina Pharmakern safe for elderly people?

A: Official guidance advises that caution and specific dose adjustments are often required for older adults. This is because age-related changes can affect the function of the kidneys or liver, which are responsible for clearing the medicine from the body. Regulatory guidance indicates that dosage requires consideration based on the individual’s physiological state.

Q: Can this combination medicine be taken if I have a history of asthma?

A: The medicine is generally used with caution or is contraindicated (prohibited) in patients with severe respiratory diseases or acute asthma. This is due to the risk that the codeine component could exacerbate (make worse) underlying breathing difficulties.

Q: What kind of common interactions are listed with herbal supplements?

A: Official patient information generally advises caution regarding the co-administration of this drug with herbal supplements. Because interactions may be unknown or undocumented, information regarding potential interactions between this medicine and specific herbal supplements is available through consultation with a healthcare professional.

Q: How quickly should I expect to feel the effect after taking this medicine?

A: Pharmacokinetic data shows that the paracetamol component typically reaches its peak concentration within approximately 10 to 60 minutes after ingestion. The codeine component, once converted in the body, generally reaches its peak concentration within about one hour. Clinical effect is generally expected to align with these timelines.

Q: Do you get withdrawal symptoms when you stop taking codeine/paracetamol?

A: If the medicine is used regularly over a prolonged period, the codeine component may cause physical dependence. Regulatory information warns that in such cases, stopping treatment suddenly may lead to withdrawal side effects, such as restlessness or irritability.

Q: Can Paracetamol + Codeina Pharmakern affect my ability to drive?

A: Yes, regulatory documents advise that caution must be exercised before driving or operating machinery. This is because the medicine commonly causes side effects like dizziness, drowsiness, or light-headedness that could impair judgment and reaction time.

Q: What signs might indicate a rare but serious side effect like liver problems?

A: The paracetamol component carries a risk of severe liver problems (hepatotoxicity), especially if the maximum dose is exceeded. Signs may include yellowing of the skin or eyes (jaundice), pain in the upper stomach area, or noticing unusually dark urine. The appearance of these symptoms is an officially documented reason to seek immediate medical attention.

Q: Why do some people metabolize codeine differently than others?

A: Differences in how the body processes codeine are due to variations in the CYP2D6 gene, which makes a liver enzyme essential for converting codeine into its active form (morphine). Official documents note the highly polymorphic nature of this gene, which results in individuals metabolizing the drug at different rates, sometimes very quickly or very slowly.

Q: Is it normal to feel a bit nauseous when starting the medication?

A: Yes, nausea is listed as a common side effect of the codeine component. Official patient information often indicates that this feeling is temporary and usually wears off after a few days as the body adjusts to the medicine.

Q: Can this drug cause dizziness or lightheadedness?

A: Yes, official regulatory documents list both dizziness and light-headedness as common documented adverse reactions. These are effects related to the action of codeine on the central nervous system.

Q: Is there a maximum number of days or weeks that this drug should be used?

A: Official documents emphasize that the product is intended for short-term use only. In several regions, regulatory guidance specifically advises against taking it for more than three consecutive days without seeking medical review.

Q: Can this medication be used for long-term chronic pain management?

A: Official regulatory guidance strictly defines this medicine for the short-term management of acute pain (pain that begins quickly and doesn't last long). Its use for long-term chronic pain is highly restricted due to the potential for tolerance, dependence, and increased risk of other adverse effects.

Q: What are the main risks associated with the codeine part of the drug?

A: The main risks associated with the codeine (opioid) component are serious. These include life-threatening respiratory depression (severe difficulty breathing) and the potential for addiction, abuse, and misuse. Regulatory agencies require strong warnings about these effects.

Q: Can I take ibuprofen or aspirin at the same time as this drug?

A: The co-administration of this medicine with other analgesics is officially identified as requiring caution. Regulatory guidance focuses on the risk of exceeding the paracetamol maximum daily limit. Taking multiple pain relievers concurrently increases this risk and requires careful medical oversight.

Q: Is the risk of side effects higher if I am overweight?

A: Regulatory warnings and precautions list obesity as a patient characteristic that may increase the risk for more serious side effects. Official guidance notes that individuals who are overweight may require greater caution and medical oversight when use of the drug is being considered.

Q: Do regulatory agencies have specific warnings about using this drug after surgery?

A: Yes, specific warnings exist. The medicine is strictly contraindicated (prohibited) in all children and adolescents following tonsillectomy or adenoidectomy. Caution is also generally advised for patients who have recently undergone gastrointestinal tract surgery.

Q: Is there any risk of allergic reaction to the inactive ingredients in the tablet?

A: Official patient information advises that individuals should not use the product if they have a known allergic reaction to the active ingredients or to any of the listed ingredients (including inactive components, or excipients). In cases where an allergy is suspected, official sources state the product is contraindicated.

Q: Can people with a history of head injury use this medicine?

A: Official regulatory documents advise that the medicine should be used with caution in patients with a history of a head injury or any condition that causes increased intracranial pressure. This is because the codeine component can affect the central nervous system.

Q: Is it possible to become tolerant to the effects of the codeine over time?

A: Regulatory information warns that use over a prolonged period of time may cause tolerance to the drug's effects. Tolerance means that a person's body may require a larger dose to achieve the same level of pain relief over time.

Q: Is this drug approved for use in all countries?

A: No, this drug's availability and regulatory status vary significantly by country. Many major regions have reclassified all codeine-containing medicines, moving them from over-the-counter status to prescription-only to ensure patient safety and medical oversight.

Q: Can this combination be taken on an empty stomach?

A: Regulatory guidance states that this medication may generally be taken with or without food. There are no general contraindications against taking the medicine on an empty stomach.

Q: Why is Paracetamol + Codeina Pharmakern a prescription-only medicine in many places?

A: Regulatory bodies have reclassified codeine-containing medicines as prescription-only in many regions to improve patient safety. This decision is based on the assessment that the associated risks, such as abuse, misuse, and overdose, outweigh the benefits of over-the-counter availability.

Q: What should I know about the potential for breathing problems with the codeine component?

A: Official warnings state the codeine component can cause life-threatening or fatal respiratory depression, which is breathing that is slow, shallow, or unusual. The risk is noted to be highest when a person first starts treatment or after a dose increase.

Q: Can this combination cause rebound headaches if taken too often?

A: Yes, regulatory documents describe that extensive use of analgesics to treat headaches, especially if taken at high doses, may itself induce headaches. This condition is sometimes referred to as medication overuse headache.

Q: Are there specific activities or sports to avoid while taking this medicine?

A: Regulatory documents advise caution before engaging in activities that require full mental alertness and quick reactions. This includes activities such as driving or operating heavy machinery, due to the potential for dizziness and drowsiness.

Q: Is Paracetamol + Codeina Pharmakern a non-steroidal anti-inflammatory drug (NSAID)?

A: No, regulatory classification places this medicine in the class of Opioid and Other Analgesics (Combination). The paracetamol component does not possess anti-inflammatory activity, which is the key characteristic of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs).

Advertisements

How should Paracetamol + Codeina Pharmakern (Acetaminophen,Codeine) be stored and disposed of?

Official Storage and Disposal Requirements

Storage and disposal must strictly follow the conditions defined in the official regulatory labeling.

Requirement Specific Condition
Temperature Store at a temperature below 25°C.
Protection Protect the tablets from light and moisture.
Container Rule Keep in the original container and original package.
Child Safety Keep out of the sight and reach of children.

Disposal of Unused Product

Paracetamol + Codeina Pharmakern must not be disposed of via wastewater or household waste. The medicine should be discarded according to local requirements for pharmaceutical waste handling. Consulting a pharmacist is recommended for information on how to properly dispose of expired or unused medication.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Paracetamol + Codeina Pharmakern (Acetaminophen,Codeine) found in:

A-Z Index: